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ABSTRACT
Background: High dietary intake or blood concentrations (as
biomarkers of dietary intake) of vitamin C, carotenoids, and
vitamin E have been associated with reduced risk of cardiovascular
disease, cancer, and mortality, but these associations have not been
systematically assessed.
Objective: We conducted a systematic review and meta-analysis of
prospective studies of dietary intake and blood concentrations of
vitamin C, carotenoids, and vitamin E in relation to these outcomes.
Design:We searched PubMed and Embase up to 14 February 2018.
Summary RRs and 95% CIs were calculated with the use of random-
effects models.
Results: Sixty-nine prospective studies (99 publications) were
included. The summary RR per 100-mg/d increment of dietary
vitamin C intake was 0.88 (95% CI: 0.79, 0.98, I2 = 65%, n = 11)
for coronary heart disease, 0.92 (95% CI: 0.87, 0.98, I2 = 68%,
n = 12) for stroke, 0.89 (95% CI: 0.85, 0.94, I2 = 27%, n = 10) for
cardiovascular disease, 0.93 (95% CI: 0.87, 0.99, I2 = 46%, n = 8)
for total cancer, and 0.89 (95% CI: 0.85, 0.94, I2 = 80%, n = 14)
for all-cause mortality. Corresponding RRs per 50-μmol/L increase
in blood concentrations of vitamin C were 0.74 (95% CI: 0.65, 0.83,
I2 = 0%, n = 4), 0.70 (95% CI: 0.61, 0.81, I2 = 0%, n = 4), 0.76
(95% CI: 0.65, 0.87, I2 = 56%, n = 6), 0.74 (95% CI: 0.66, 0.82,
I2 = 0%, n = 5), and 0.72 (95% CI: 0.66, 0.79, I2 = 0%, n = 8).
Dietary intake and/or blood concentrations of carotenoids (total, β-
carotene, α-carotene, β-cryptoxanthin, lycopene) and α-tocopherol,
but not dietary vitamin E, were similarly inversely associated with
coronary heart disease, stroke, cardiovascular disease, cancer, and/or
all-cause mortality.
Conclusions: Higher dietary intake and/or blood concentrations of
vitamin C, carotenoids, and α-tocopherol (as markers of fruit and
vegetable intake) were associated with reduced risk of cardiovascular
disease, total cancer, and all-cause mortality. These results support
recommendations to increase fruit and vegetable intake, but not
antioxidant supplement use, for chronic disease prevention. Am
J Clin Nutr 2018;108:1069–1091.
Keywords: vitamin C, carotenoids, beta-carotene, vitamin E,
coronary heart disease, stroke, cardiovascular disease, cancer,
mortality, meta-analysis
INTRODUCTION
Worldwide cardiovascular disease and cancer accounted for
25.5 million deaths in 2013 (1). A high intake of fruits,
vegetables, and nuts has been associated with reduced risk of
cardiovascular disease, cancer, and mortality (2–11) and these
findings provide a basis for dietary recommendations to prevent
chronic diseases and premature mortality (9).
Fruit, vegetables, berries, herbs, nuts, and legumes contain a
number of nutrients that have been hypothesized to contribute
to their purported beneficial effects including fiber, vitamin
C, vitamin E, carotenoids, flavonoids, potassium, and a large
number of other components (12). Dietary intake as well
as blood concentrations of some of these nutrients including
vitamin C, vitamin E, and carotenoids have been related to
risk of cardiovascular disease, cancer, and all-cause mortality
(13–28). Blood concentrations of vitamin C and carotenoids
are considered biomarkers of fruit and vegetable intake (29–
31) and studies that use biomarkers of fruit and vegetable
intake complement questionnaire-based studies by providing
Am J Clin Nutr 2018;108:1069–1091. Printed in USA. © 2018 American Society for Nutrition. This is an Open Access article distributed under the terms of the
Creative CommonsAttribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution,
and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. 1069
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/108/5/1069/5201459 by U
niversity of Leeds user on 15 January 2019
1070 AUNE ET AL.
an integrated measure of both intake and absorption (32).
Many prospective studies have investigated the association
between dietary antioxidants including vitamin C, vitamin E,
and carotenoids and coronary heart disease (13, 14, 33–43),
stroke (13, 41, 44–52), cardiovascular disease overall (41, 53–
56), total cancer (14, 20, 36, 53, 56, 57), and all-cause mortality
(14, 19, 36, 38, 53, 54, 56, 58–60), but studies are not entirely
consistent with some showing an inverse association (14, 36,
38, 39, 41, 43, 47, 48, 54, 55, 57, 58) and others reporting
no significant association (19, 33–35, 37, 40, 42, 44–46, 49–
53, 56, 59–61). Some of the previous studies may have been
too small and therefore underpowered to find a significant
association (20, 33, 35, 44, 49, 50, 52, 53, 59). In addition,
some degree of measurement error and regression dilution bias
is inevitable in dietary studies and may at least to some degree
have attenuated some findings in previous studies. Aune et al. (62)
recently reported stronger inverse associations between blood
concentrations of carotenoids when compared with dietary intake
as measured by food frequency questionnaires in relation to
breast cancer risk. There was only a 5–6% reduction in the
RR for the highest compared with the lowest dietary intake of
carotenoids; however, when blood concentrations of carotenoids
were analyzed there was a 25–30% reduction in the RR for those
with the highest compared with the lowest concentrations (62)
and similar results have been found in pooled analyses (63, 64).
One meta-analysis also suggested an inverse association between
dietary intake and blood concentrations of vitamin C and risk
of stroke (65). However, whether or not blood concentrations
of different types of antioxidants are associated with risk of
cardiovascular disease, total cancer, and mortality is not clear
(13–25, 28) and has not previously been comprehensively
evaluated across multiple exposures and outcomes in a meta-
analysis. For these reasons we conducted a meta-analysis of
dietary intake and blood concentrations of vitamin C (ascorbic
acid), vitamin E (tocopherol), and carotenoids (total carotenoids,
α-carotene, β-carotene, lycopene, β-cryptoxanthin) and the
risk of coronary heart disease, stroke, cardiovascular disease,
total cancer, and all-cause mortality, and specifically aimed
to clarify the strength and the shape of the dose-response
relation.
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METHODS
Search strategy
We searched the PubMed and Embase databases from their
inception to 31 May 2014 using a comprehensive list of search
terms shown in Supplemental Table 1 and the searches were
later updated to 14 February 2018. There was no protocol
for the current review. We included prospective cohort studies
and nested case-control studies that reported adjusted RR
estimates (ORs, HRs, incidence rate ratios, or risk ratios) of the
association between vitamin C, vitamin E, and carotenoids in
the diet or measured in blood and the risk of coronary heart
disease, stroke, cardiovascular disease, total cancer, and all-cause
mortality. Studies that only assessed supplemental intake of these
antioxidants were excluded. For the dose-response analysis a
quantitative measure of intake or the blood concentrations for
≥3 categories had to be available. A list of the excluded studies
and reasons for exclusion is found in Supplemental Table 2.
Standard criteria for reporting meta-analyses were followed (66).
Data extraction
We extracted the following data from each study: first author’s
last name, publication year, country where the study was
conducted, study name, follow-up period, sample size, sex, age,
number of cases or deaths, dietary assessment method (type,
number of items, and whether it was validated), laboratory
method for analysis of antioxidants in blood, exposure, exposure
dose, RRs and 95%CIs, and variables adjusted for in the analysis.
DA conducted the data extraction and NK and LTF checked the
extractions for accuracy.
Statistical methods
To take into account heterogeneity between studies, we used a
random-effects model to calculate summary RRs and 95% CIs
for the highest compared with the lowest level of antioxidant
exposure and for the dose-response analysis (67). The average
of the natural logarithm of the RRs was estimated, and the RR
from each study was weighted with the use of random-effects
weighting. A 2-tailed P < 0.05 was considered statistically
significant.
Details of the methods for the dose-response analysis have
been published elsewhere (62). Briefly, we used the method
described by Greenland and Longnecker (68) to compute linear
trends and 95% CIs from the natural logs of the RRs and
CIs across categories of antioxidant exposure. We used mean
or median values when provided in the papers, but used the
midpoint of the upper and lower boundaries when the exposure
was provided as a range. When the highest and lowest categories
were open-ended or had extreme upper or lower values we used
the width of the adjacent interval to estimate the upper and lower
boundaries for the category. For studies that did not report the
distribution of cases and person-years or noncases we estimated
the distribution by dividing the total number of cases or person-
years by the number of categories. For studies that reported
plasma or serum concentrations of carotenoids, α-carotene,
β-carotene, or lycopene inµmol/Lwe converted the data toµg/dL
by dividing the concentration inµmol/L by 0.01863 (69), whereas
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for studies of β-cryptoxanthin we divided the concentration in
µmol/L by 0.01809. For studies of vitamin E, data in µmol/Lwere
divided by 232.2 to convert the data to µg/dL (70). For the linear
dose-response analysis we used an increment with the size of
the approximate mean difference between the highest and lowest
level of exposure across studies.
A potential nonlinear dose-response relation between antioxi-
dant exposures and cardiovascular disease, cancer, and mortality
was examined with the use of restricted cubic splines with 3 knots
at 10th, 50th, and 90th percentiles of the distribution, which was
combined with the use of multivariate meta-analysis (71, 72). A
likelihood ratio test was used to assess the difference between the
nonlinear and linear models to test for nonlinearity (73).
Heterogeneity between studies was assessed through the use of
Q and I2 statistics (74).We conducted subgroup analyses by study
characteristics including duration of follow-up, sex, geographic
location, number of cases, study quality, exclusion of prevalent
cases of diseases at baseline, and adjustment for confounders,
as well as influence analyses to investigate the robustness of the
results when there were≥6 studies in the dose-response analysis.
Study quality was assessed with the use of the Newcastle-
Ottawa Scale, which awards 0–9 stars based on the selection,
comparability, and outcome assessment (75). Small-study effects,
such as publication bias, were assessed with the use of a funnel
plot and Egger’s test, with results considered to indicate potential
small-study bias when P< 0.10 (76). Stata version 13.0 software
(StataCorp) was used for the statistical analyses.
RESULTS
A total of 69 prospective studies (99 publications) (13–28,
33–61, 70, 77–127) were included in the analyses of dietary
(includes total intake and dietary intake only) antioxidant intake
and blood concentrations of antioxidants and coronary heart
disease, stroke, cardiovascular disease, cancer, and mortality
(Supplemental Tables 3–12, Figure 1). Thirty-six of the
studies were from Europe, 24 from America, and 9 studies
were from Asia (Supplemental Tables 3–12). One publication
included combined results from two studies (53) and another
publication included results from two studies (81). Because
some studies only reported a high against low comparison or
a continuous estimate, the number of studies included for each
exposure and outcome comparison in the high against low
and dose-response analyses may differ slightly from the total
number of studies included in the analysis of each exposure
and outcome. The number of studies, cases or deaths, and
participants and references for studies included in each analysis
are provided in Table 1. Supplemental Tables 3–12 show a
summary of the study characteristics of the included studies.
Supplemental Tables 13–24 show the results of the nonlinear
dose-response analyses and Supplemental Tables 25–34 show
the results of the subgroup analyses. Figure 1 shows a flow
chart of the study selection. Figures 2–14 show the results
for the dose-response analyses of vitamin C and β-carotene
in relation to all outcomes and carotenoids and vitamin E in
relation to all-cause mortality. Supplemental Figures 1–95
show the results of the high against low analysis as well as
dose-response results for the remaining antioxidant exposures
and outcomes. Supplemental Figures 96–107 show the funnel
plots from the tests for publication bias and Supplementary
FIGURE 1 Flow chart of study selection. COPD, chronic obstructive
pulmonary disease.
Figures 108–125 shows the results from the influence analyses
excluding one study at a time.
Dietary vitamin C intake
Twelve (13, 14, 33–41, 49), thirteen (41, 44–52, 58, 61,
123), eleven (9 publications) (19, 26, 41, 53–56, 80, 81), nine
(7 publications) (14, 20, 36, 53, 56, 57, 81), and seventeen
(16 publications) (14, 19, 20, 36, 38, 53, 54, 56, 58–60,
81–84, 127) studies were included in the analysis of dietary
vitamin C intake and risk of coronary heart disease, stroke,
cardiovascular disease, total cancer, and all-cause mortality,
respectively. A statistically significant 12%, 8%, 11%, 7%,
and 11% reduction in the RR was observed for coronary
heart disease, stroke, cardiovascular disease, total cancer, and
mortality (Figures 2A–6A, Table 1, Supplemental Figures 1–5),
respectively. There was evidence of nonlinearity for coronary
heart disease (Pnonlinearity < 0.0001), stroke (Pnonlinearity < 0.0001),
cardiovascular disease (Pnonlinearity < 0.0001), total cancer
(Pnonlinearity = 0.006), and mortality (Pnonlinearity < 0.0001) with
stronger reductions in risk at lower amounts of intake in all
analyses (Figures 2C–6C, Supplemental Table 13).
Vitamin C in blood
Four (13–15, 92), five (16, 17, 58, 87, 98), six (18–22, 103), six
(14, 18, 20–22, 116), and eight (9 publications) (14, 18–23, 58,
126) studies were included in the analysis of blood concentrations
of vitamin C and risk of coronary heart disease, stroke,
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 Gale, 1995 (13)   0.67 ( 0.36, 1.26)
 Pandey, 1995 (36)   0.85 ( 0.69, 1.06)
 Knekt, 1994 (35)   0.78 ( 0.56, 1.07)
 Fehily, 1993 (33)   0.60 ( 0.21, 1.67)
 Rimm, 1993 (34)   1.01 ( 0.99, 1.04)
 Overall   0.88 ( 0.79, 0.98)
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 Sahyoun, 1996 (14)   0.67 ( 0.49, 0.92)
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 Overall   0.74 ( 0.65, 0.83)
FIGURE 2 Dietary intake and blood concentrations of vitamin C and coronary heart disease: dose-response analyses. (A) Dietary vitamin C and coronary
heart disease: linear dose-response analysis. The summary RR per 100 mg/d was 0.88 (95% CI: 0.79, 0.98, I2 = 65%, Pheterogeneity = 0.001, n = 11). (B)
Vitamin C in blood and coronary heart disease: linear dose-response analysis. The summary RR per 50 µmol/L was 0.74 (95% CI: 0.65, 0.83, I2 = 0%,
Pheterogeneity = 0.71, n = 4). (C) Dietary vitamin C and coronary heart disease: nonlinear dose-response analysis. There was evidence of nonlinearity between
dietary vitamin C and coronary heart disease (Pnonlinearity < 0.0001). (D) Vitamin C in blood and coronary heart disease: nonlinear dose-response analysis.
There was no evidence of nonlinearity for vitamin C in blood and coronary heart disease (Pnonlinearity = 0.49). Summary RRs and 95% CIs were calculated
with the use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of restricted cubic splines.
cardiovascular disease, total cancer, and mortality, respectively.
Inverse associations were observed for all outcomes, with
24–30% reductions in the RR (Figures 2B–6B, Supplemental
Figures 6–10). There was evidence of a nonlinear association
between vitamin C in blood and total cancer (Pnonlinearity = 0.006),
with stronger inverse associations at lower vitamin C concen-
trations but not for coronary heart disease (P = 0.49), stroke
(Pnonlinearity = 0.16), cardiovascular disease (Pnonlinearity = 0.26),
or mortality (Pnonlinearity = 0.90) (Figures 2D–6D, Supplemental
Table 14).
Total dietary carotenoid intake
Five (14, 34, 35, 37, 42), four (3 publications) (20, 55, 81),
four (3 publications) (14, 20, 81), and six (5 publications) (14,
20, 42, 54, 81) studies were included in the analysis of total
dietary carotenoid intake and risk of coronary heart disease,
cardiovascular disease, total cancer, and mortality, respectively.
A statistically significant 15%, 20%, and 12% reduction in the
RR was observed for coronary heart disease, cardiovascular
disease, and mortality (Figure 7A, Table 1, Supplemental Figures
11A, 12, 13, 14A, and 17), respectively, but no association
was observed for total cancer (Table 1, Supplemental Figures
15 and 16A). There was evidence for a nonlinear association
between total carotenoid intake and cardiovascular disease
(Pnonlinearity = 0.002), total cancer (Pnonlinearity = 0.01), and
mortality (Pnonlinearity < 0.0001), but not for coronary heart
disease (Pnonlinearity = 0.95) (Figure 7B, Supplemental Table 15,
Supplemental Figures 11B, 14B, and 16B), with most of the
reduction in risk observed up to an intake of between 4000 and
6000 µg/d.
Total carotenoids in blood
Four (14, 87, 88, 90), two (108, 109), three (14, 108, 110),
and seven (14, 24, 25, 107, 108, 121, 125) studies were included
in the analyses of blood concentrations of total carotenoids
and risk of coronary heart disease, cardiovascular disease, total
cancer, and mortality, respectively. A statistically significant 17%
and 31% reduction in RR was observed for coronary heart
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 Kubota, 2011 (41)   0.83 ( 0.74, 0.94)
 Weng, 2008 (50)   0.92 ( 0.82, 1.03)
 Marniemi, 2005 (49)   0.95 ( 0.62, 1.45)
 Voko, 2003 (48)   0.74 ( 0.59, 0.93)
 Hirvonen, 2000 (47)   0.88 ( 0.78, 1.00)
 Yochum, 2000 (46)   1.06 ( 0.99, 1.13)
 Ascherio, 1999 (45)   1.00 ( 0.97, 1.03)
 Daviglus, 1997 (52)   0.75 ( 0.50, 1.10)
 Gale, 1996 (58)   0.38 ( 0.17, 0.87)
 Keli, 1996 (44)   1.01 ( 0.55, 1.87)
 Overall   0.92 ( 0.87, 0.98)
FIGURE 3 Dietary intake and blood concentrations of vitamin C and stroke: dose-response analyses. (A) Dietary vitamin C and stroke: linear dose-
response analysis. The summary RR per 100 mg/d was 0.92 (95% CI: 0.87, 0.98, I2 = 68%, Pheterogeneity < 0.0001, n= 12). (B) Vitamin C in blood and stroke:
linear dose-response analysis. The summary RR per 50 µmol/L was 0.70 (95% CI: 0.61, 0.81, I2 = 0%, Pheterogeneity = 0.41, n= 4). (C) Dietary vitamin C and
stroke: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary vitamin C and stroke (Pnonlinearity < 0.0001). (D) Vitamin C in
blood and stroke: nonlinear dose-response analysis. There was no evidence of nonlinearity for vitamin C in blood and stroke (Pnonlinearity = 0.16). Summary
RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of restricted
cubic splines.
disease and mortality, respectively, and a significant association
was observed for total cancer only in the high compared with
low analysis and the nonlinear dose-response analysis (Table 1,
Figure 7B, Supplemental Figures 18A, 19, and 22A–24), whereas
the association for cardiovascular disease only was significant
in the nonlinear analysis (Table 1, Supplemental Figures 20 and
21, Supplemental Table 16). There was evidence of a nonlinear
association for coronary heart disease (Pnonlinearity = 0.008) and
cardiovascular disease (Pnonlinearity = 0.004), but not for total can-
cer (Pnonlinearity = 0.33) or mortality (Pnonlinearity = 0.73) (Figure 7,
Supplemental Figures 18D, 20D, and 22D, Supplemental Table
16).
Dietary β-carotene
Four (36, 38, 39, 43), seven (44, 45, 47, 48, 51, 52, 123), six
(5 publications) (19, 53, 55, 56, 80), five (4 publications) (36, 53,
56, 57), and seven (6 publications) (36, 38, 53, 54, 56, 60) studies
were included in the analysis of dietary β-carotene intake and risk
of coronary heart disease, stroke, cardiovascular disease, total
cancer, and mortality, respectively. Dietary β-carotene was asso-
ciated with 8–19% reductions in the RRs of coronary heart dis-
ease, stroke, and mortality in the dose-response analysis (Table 1,
Figures 8A, 9A, and 12A, Supplemental Figures 25, 26, and
29), but there was no association for cardiovascular disease
and total cancer (Figures 10A and 11A, Table 1, Supplemental
Figures 27 and 28). There was evidence of a nonlinear
association between β-carotene intake and coronary heart disease
(Pnonlinearity = 0.006), stroke (Pnonlinearity < 0.0001), total cancer
(Pnonlinearity = 0.003), and mortality (Pnonlinearity < 0.0001), with
a stronger reduction in risk at the lower amounts of intake,
but there was no evidence of an association or nonlinearity for
cardiovascular disease (Pnonlinearity = 0.51) (Figures 8C–12C,
Supplemental Table 17).
β-Carotene in blood
Four (89, 91, 93, 95), three (97, 99, 100), seven (19–21,
27, 103, 106, 109), seven (20, 21, 27, 28, 115, 117, 120),
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 Stepaniak, 2016 (56)   0.96 ( 0.89, 1.04)
 De Oliveira Otto, 2012 (80)   1.10 ( 0.82, 1.48)
 Bates, 2011 (20)   0.89 ( 0.72, 1.13)
 Kubota, 2011 (41)   0.87 ( 0.80, 0.95)
 Buijsse, 2008 (55)   0.90 ( 0.65, 1.24)
 Genkinger, 2004 (53)   1.00 ( 0.85, 1.18)
 Fletcher, 2003 (19)   1.00 ( 0.62, 1.60)
 Overall   0.89 ( 0.85, 0.94)
FIGURE 4 Dietary intake and blood concentrations of vitamin C and cardiovascular disease: dose-response analyses. (A) Dietary vitamin C and
cardiovascular disease: linear dose-response analysis. The summary RR per 100 mg/d was 0.89 (95% CI: 0.85, 0.94, I2 = 27%, Pheterogeneity = 0.19, n = 10).
(B) Vitamin C in blood and cardiovascular disease: linear dose-response analysis. The summary RR per 50 µmol/L was 0.76 (95% CI: 0.65, 0.87, I2 = 56%,
Pheterogeneity = 0.05, n = 6). (C) Dietary vitamin C and cardiovascular disease: nonlinear dose-response analysis. There was evidence of nonlinearity between
dietary vitamin C and cardiovascular disease (Pnonlinearity < 0.0001). (D) Vitamin C in blood and cardiovascular disease: nonlinear dose-response analysis.
There was no evidence of nonlinearity for vitamin C in blood and cardiovascular disease (Pnonlinearity = 0.26). Summary RRs and 95% CIs were calculated with
the use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of restricted cubic splines. SMHS, Shanghai Men’s
Health Study; SWHS, Shanghai Women’s Health Study.
and seven (19–21, 27, 117, 121, 124) studies were included
in the analysis of blood concentrations of β-carotene and risk
of coronary heart disease, stroke, cardiovascular disease, total
cancer, and mortality, respectively. A 15–24% reduction in
RR was observed for blood concentrations of β-carotene in
relation to all outcomes (Table 1, Figures 8B–12B, Supplemental
Figures 30–34). There was indication of a nonlinear associ-
ation for coronary heart disease (Pnonlinearity = 0.002), stroke
(Pnonlinearity = 0.07), cardiovascular disease (Pnonlinearity = 0.006),
and mortality (Pnonlinearity = 0.005), with stronger associations
at the lower β-carotene concentrations, but not for total
cancer (Pnonlinearity = 0.60) (Figures 8D–12D, Supplemental
Table 18).
Dietary α-carotene
Two (45, 123) and two (54, 123) studies were included
in the analysis of dietary α-carotene and risk of stroke and
mortality, respectively. There was a 22% reduction in the RR of
mortality for high compared with low intake of α-carotene, but no
association was observed for stroke (Supplemental Figures 35–
37).
α-Carotene in blood
Four (91, 93–95), three (94, 99, 100), five (20, 94, 106, 108,
109), four (5 publications) (20, 94, 117, 118, 120), and five
(20, 24, 94, 117, 121) studies were included in the analysis
of blood concentrations of α-carotene and risk of coronary
heart disease, stroke, cardiovascular disease, total cancer, and
mortality, respectively. A 42% and 29% reduction in RR for total
cancer and mortality was observed for α-carotene in blood, but
no association was observed for coronary heart disease, stroke,
or cardiovascular disease (Figure 13A, Table 1, Supplemental
Figures 38–46). There was evidence of nonlinear associations
for coronary heart disease (Pnonlinearity = 0.01), cardiovascular
disease (Pnonlinearity <0.0001), total cancer (Pnonlinearity < 0.0001),
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/108/5/1069/5201459 by U
niversity of Leeds user on 15 January 2019
1078 AUNE ET AL.
95% CI
μ
CI
FIGURE 5 Dietary intake and blood concentrations of vitamin C and total cancer: dose-response analyses. (A) Dietary vitamin C and total cancer: linear
dose-response analysis. The summary RR per 100 mg/d was 0.93 (95% CI: 0.87, 0.99, I2 = 46%, Pheterogeneity = 0.08, n = 8). (B) Vitamin C in blood
and total cancer: linear dose-response analysis. The summary RR per 50 µmol/L was 0.74 (95% CI: 0.66, 0.82, I2 = 0%, Pheterogeneity = 0.49, n = 5).
(C) Dietary vitamin C and total cancer: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary vitamin C and total cancer
(Pnonlinearity = 0.007). (D) Vitamin C in blood and total cancer: nonlinear dose-response analysis. There was evidence of nonlinearity for vitamin C in blood
and total cancer (Pnonlinearity = 0.006). Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response
analyses were conducted with the use of restricted cubic splines. SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study.
andmortality (Pnonlinearity < 0.0001), with stronger inverse associ-
ations at the lower blood concentrations than at higher blood con-
centrations, but not for stroke (Pnonlinearity = 0.87) (Figure 13D,
Supplemental Figures 38B, 40B, 42B, and 44B, Supplemental
Table 19).
Dietary β-cryptoxanthin
Two studies (54, 123) were included in the high compared with
low analysis of dietary β-cryptoxanthin and mortality. There was
a 26% reduction in the RR for high compared with low intake
(Supplemental Figure 47).
β-Cryptoxanthin in blood
Two (91, 93), four (20, 104, 106, 108), three (20, 108,
120), and three (20, 108, 121) studies were included in the
analyses of blood concentrations of β-cryptoxanthin and risk
of coronary heart disease, cardiovascular disease, total cancer,
and mortality, respectively. A 26% and 16% reduction in the
RR of total cancer and mortality was observed, respectively,
but no significant association was observed for coronary heart
disease and cardiovascular disease (Figure 13B, Table 1,
Supplemental Figures 48–54). There was evidence of a nonlinear
association between β-cryptoxanthin in blood and coronary heart
disease (Pnonlinearity = 0.01), but not for cardiovascular disease
(Pnonlinearity = 0.20) or mortality (Pnonlinearity = 0.98) (Figure 13E,
Supplemental Figures 48B and 50B, Supplemental Table 20).
Dietary lutein
Two (54, 127) studies were included in the high compared
with low analysis of dietary lutein and mortality and there was
no significant association (Supplemental Figure 55).
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Vitamin C in blood (μmol/L)
95% CI95% CI
FIGURE 6 Dietary intake and blood concentrations of vitamin C and mortality: dose-response analyses. (A) Dietary vitamin C and mortality: linear dose-
response analysis. The summary RR per 100mg/d was 0.89 (95%CI: 0.85, 0.94, I2 = 80%,Pheterogeneity < 0.0001, n= 14). (B) Vitamin C in blood andmortality:
linear dose-response analysis. The summary RR per 50 µmol/L was 0.72 (95% CI: 0.66, 0.79, I2 = 48%, Pheterogeneity = 0.06, n= 8). (C) Dietary vitamin C and
mortality: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary vitamin C and mortality (Pnonlinearity < 0.0001). (D) Vitamin
C in blood and mortality: nonlinear dose-response analysis. There was no evidence of nonlinearity for vitamin C in blood and mortality (Pnonlinearity = 0.90).
Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of
restricted cubic splines. SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study.
Lutein in blood
Three (89, 91, 93) studies were included in the high compared
with low analysis of lutein in blood and risk of coronary heart
disease and there was no significant association (Supplemental
Figure 56).
Dietary zeaxanthin
Two (89, 93) and two (54, 127) studies were included in the
high compared with low analysis of dietary zeaxanthin and risk of
coronary heart disease and mortality, respectively, and there was
no significant association in both analyses (Supplemental Figures
57 and 58).
Lutein and zeaxanthin in blood
Four (20, 104, 106, 108), three (20, 108, 118), and two
(20, 108) studies were included in the analyses of lutein and
zeaxanthin in blood and risk of cardiovascular disease, total
cancer, andmortality, respectively. No significant association was
observed in all analyses (Supplemental Figures 59–62).
Dietary lycopene
Two (43, 78), three (45, 47, 78), and two (55, 78) studies were
included in the analysis of dietary lycopene and risk of coronary
heart disease, stroke, and cardiovascular disease. No studies were
identified for total cancer, and only 2 were identified for mortality
(54, 127), but dose-response analyses were not possible. There
was no association between dietary lycopene and coronary heart
disease, stroke, cardiovascular disease, or all-cause mortality
(Table 1, Supplemental Figures 63–68). There was no evidence
of a nonlinear association between lycopene intake and coronary
heart disease (Pnonlinearity = 0.97) or stroke (Pnonlinearity = 0.81)
(Supplemental Figures 63B and 65B, Supplemental Table 21).
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FIGURE 7 Dietary intake and blood concentrations of carotenoids and mortality: dose-response analyses. (A) Dietary carotenoids and mortality: linear
dose-response analysis. The summary RR per 5000 µg/d was 0.88 (95% CI: 0.83, 0.93, I2 = 2%, Pheterogeneity = 0.40, n = 6). (B) Carotenoids in blood and
mortality: linear dose-response analysis. The summary RR per 50 µg/dL was 0.69 (95% CI: 0.59, 0.81, I2 = 50%, Pheterogeneity = 0.04, n = 10). (C) Dietary
carotenoids and mortality: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary carotenoids and mortality (Pnonlinearity = 0.01).
(D) Carotenoids in blood and mortality: nonlinear dose-response analysis. There was no evidence of nonlinearity for vitamin C in blood and mortality
(Pnonlinearity = 0.73). Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response analyses were
conducted with the use of restricted cubic splines. SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study.
Lycopene in blood
Three (91, 93, 95), two (93, 95), five (20, 95, 104, 106,
108), five (20, 108, 117, 119, 120), and five (20, 108, 117, 121,
124) studies were included in the analysis of blood concentra-
tions of lycopene and risk of coronary heart disease, stroke,
cardiovascular disease, total cancer, and mortality, respectively.
There was no significant association between lycopene in blood
and any of the outcomes in the linear dose-response analyses
or high and low analyses (Figure 13C, Table 1, Supplemental
Figures 69–77). Although the test for nonlinearity was not
significant for coronary heart disease (Pnonlinearity = 0.30), there
was indication of a nonlinear association between lycopene in
blood and stroke (Pnonlinearity < 0.0001), cardiovascular disease
(Pnonlinearity = 0.005), total cancer (Pnonlinearity < 0.0001), and
mortality (Pnonlinearity = 0.001), and most of the reduction in
risk was observed at the lower range of lycopene concentrations
(Figure 13F, Supplemental Figures 69B, 71B, 73B, and 75B,
Supplemental Table 22).
Dietary vitamin E
Nine (14, 34, 35, 37–39, 41, 49, 77), ten (41, 44–48, 49,
51, 61, 123), nine (7 publications) (20, 41, 53, 55, 56, 80,
81), seven (5 publications) (14, 20, 53, 56, 81), and eleven (9
publications) (14, 19, 20, 38, 53, 54, 56, 81, 127) studies were
included in the analysis of dietary vitamin E (including both diet
and total vitamin E) and risk of coronary heart disease, stroke,
cardiovascular disease, total cancer, and mortality, respectively.
Dietary vitamin E was not significantly associated with any
of the outcomes in the linear dose-response analysis (Table 1,
Figure 14A, Supplemental Figures 78–86). However, there was
indication of nonlinearity between vitamin E and coronary heart
disease (Pnonlinearity < 0.0001), stroke (Pnonlinearity < 0.0001),
cardiovascular disease (Pnonlinearity < 0.0001), total cancer
(Pnonlinearity = 0.003), and mortality (Pnonlinearity < 0.0001)
(Figure 14, Supplemental Figures 78C, 80C, 82C, and 84C,
Supplemental Table 23), with stronger reductions in risk at lower
amounts of intake.
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FIGURE 8 Dietary β-carotene and blood concentrations of β-carotene and coronary heart disease: dose-response analyses. (A) Dietary β-carotene and
coronary heart disease: linear dose-response analysis. The summary RR per 5000 µg/d was 0.82 (95% CI: 0.68, 0.98, I2 = 45%, Pheterogeneity = 0.14, n = 4).
(B) β-Carotene in blood and coronary heart disease: linear dose-response analysis. The summary RR per 25 µg/dL was 0.76 (95% CI: 0.62, 0.93, I2 = 22%,
Pheterogeneity = 0.28, n = 4). (C) Dietary β-carotene and coronary heart disease: nonlinear dose-response analysis. There was evidence of nonlinearity between
dietary β-carotene and coronary heart disease (Pnonlinearity = 0.006). (D) β-Carotene in blood and coronary heart disease: nonlinear dose-response analysis.
There was evidence of nonlinearity for β-carotene in blood and coronary heart disease (Pnonlinearity = 0.002). Summary RRs and 95% CIs were calculated with
the use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of restricted cubic splines.
α-Tocopherol in blood
Five (14, 90, 91, 95, 96), four (96, 97, 99, 100), seven (19–
21, 70, 79, 103, 107), eight (9 publications) (14, 20, 21, 70, 107,
110, 112–114), and eight (14, 19–21, 70, 107, 121, 124) studies
were included in the analysis of α-tocopherol in blood and risk
of coronary heart disease, stroke, cardiovascular disease, total
cancer, and mortality, respectively. There was a 10%, 9%, and
6% reduction in the risk of stroke, total cancer, and mortality,
respectively, for each 500-μg/dL increase in blood concentrations
of α-tocopherol, but no significant association was observed for
coronary heart disease or cardiovascular disease overall (Figure
14B, Supplemental Figures 78B, 80B, 82B, 84B, and 87–91).
The test for nonlinearity was significant for coronary heart
disease (Pnonlinearity = 0.02) and mortality (Pnonlinearity = 0.05),
but not for stroke (Pnonlinearity = 0.79), cardiovascular disease
(Pnonlinearity = 0.32), or total cancer (Pnonlinearity = 0.59)
(Figure 14, Supplemental Figures 78D, 80D, 82D, and 84D,
Supplemental Table 24).
γ-Tocopherol in blood
Three (90, 91, 96) and two (91, 96) studies were included in
the analyses of γ -tocopherol in blood and coronary heart disease
and stroke, respectively. No significant association was observed
in both analyses (Supplemental Figures 92–95).
Publication bias, subgroup and sensitivity analyses, influence
analyses, study quality.
There was evidence of publication bias in the following
analyses: dietary vitamin C and coronary heart disease, stroke,
and all-cause mortality; carotenoids in blood and all-cause
mortality; dietary β-carotene and stroke, total cancer, and all-
cause mortality; α-carotene in blood and all-cause mortality;
lycopene in blood and all-cause mortality; and dietary vitamin E
and cardiovascular disease, total cancer, and all-cause mortality
(Supplemental Figures 96–107).
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 Daviglus, 1997 (52)   0.85 ( 0.57, 1.27)
 Keli, 1996 (44)   0.17 ( 0.01, 1.99)
 Overall   0.81 ( 0.66, 0.98)
FIGURE 9 (A) Dietary β-carotene and stroke: linear dose-response analyses. The summary RR per 5000 µg/d was 0.81 (95% CI: 0.66, 0.98, I2 = 59%,
Pheterogeneity = 0.02, n = 7). (B) β-Carotene in blood and stroke: linear dose-response analysis. The summary RR per 25 µg/dL was 0.85 (95% CI: 0.74, 0.97,
I2 = 0%, Pheterogeneity = 0.50, n= 3). (C) Dietary β-carotene and stroke: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary
β-carotene and stroke (Pnonlinearity < 0.0001). (D) β-Carotene in blood and stroke: nonlinear dose-response analysis. There was evidence of nonlinearity for
β-carotene in blood and stroke (Pnonlinearity = 0.07). Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear
dose-response analyses were conducted with the use of restricted cubic splines.
In stratified analyses there was little evidence of hetero-
geneity between subgroups of studies that investigated vitamin
C intake and coronary heart disease, stroke, cardiovascular
disease, total cancer, or mortality (Supplemental Tables 25–
26). In the analysis of blood concentrations of vitamin C
and cardiovascular disease there was evidence of heterogene-
ity among subgroups of studies that excluded subjects with
prevalent disease at baseline (P = 0.04), with a stronger
association among studies with such exclusions compared
with those without (Supplemental Table 27). In the analysis
of blood concentrations of vitamin C and mortality, there
was heterogeneity by duration of follow-up (P = 0.02),
with a weaker association among studies with longer follow-
up than among studies with shorter follow-up (Supplemental
Table 27), and by geographic location (P= 0.02), with a stronger
association among European studies than among American
studies. There was also heterogeneity between subgroups which
adjusted for education, smoking, alcohol, BMI, physical activity,
hypertension, and serum cholesterol (Pheterogeneity = 0.02 or
0.03 for all) (Supplemental Table 27), with weaker associations
among studies with such adjustment; however, the inverse
associations persisted among studies with such adjustment. There
was no between-subgroup heterogeneity for carotenoids in blood
and mortality (Supplemental Table 29), dietary β-carotene and
stroke (Supplemental Table 30), and β-carotene in blood and
cardiovascular disease, total cancer, and mortality (Supplemental
Table 31), and little evidence of heterogeneity among studies
of vitamin E and coronary heart disease, stroke, cardiovascular
disease, total cancer, and all-cause mortality (Supplemental
Tables 32–33), and among studies of α-tocopherol in blood and
cardiovascular disease, total cancer, and mortality (Supplemental
Table 34).
In further influence analyses excluding 1 study at a time, most
of the associations were robust to the influence of individual
studies (Supplemental Figures 108–125).
The study quality of the included studies was, in general, high
as the vast majority of the included studies were in the subgroup
with 7–9 points (Supplemental Tables 25–34).
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FIGURE 10 Dietary β-carotene and blood concentrations of β-carotene and cardiovascular disease: dose-response analyses. (A) Dietary β-carotene and
cardiovascular disease: linear dose-response analysis. The summary RR per 5000 µg/d was 0.87 (95% CI: 0.63, 1.20, I2 = 58%, Pheterogeneity = 0.10, n = 3).
(B) β-Carotene in blood and cardiovascular disease: linear dose-response analysis. The summary RR per 25 µg/dL was 0.85 (95% CI: 0.76, 0.95, I2 = 9%,
Pheterogeneity = 0.36, n= 7). (C) Dietary β-carotene and cardiovascular disease: nonlinear dose-response analysis. There was no evidence of nonlinearity between
dietary β-carotene and cardiovascular disease (Pnonlinearity = 0.51). (D) β-Carotene in blood and cardiovascular disease: nonlinear dose-response analysis. There
was evidence of nonlinearity for β-carotene in blood and cardiovascular disease (Pnonlinearity = 0.006). Summary RRs and 95% CIs were calculated with the
use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of restricted cubic splines.
DISCUSSION
This meta-analysis showed an inverse association between
dietary intake and blood concentrations of vitamin C and
risk of coronary heart disease, stroke, cardiovascular disease
overall, total cancer, and all-cause mortality. Vitamin C is found
abundantly in fruits, vegetables, especially berries, citrus fruits
and juices, kiwi, broccoli, and peppers and some legumes
(green beans), as well as dietary supplements. Plasma ascorbic
acid correlates with intake of fruit and vegetables (22, 98,
128), especially citrus fruit and citrus fruit juices (14, 129),
and epidemiological studies have found a reduced risk of
cardiovascular disease, total cancer, and/or all-cause mortality
with a high intake of these foods (11).
Dietary carotenoid intake as well as intake of specific
carotenoids (β-carotene, lycopene) were inversely associated
with coronary heart disease, stroke, and mortality, whereas blood
concentrations of carotenoids (total, β-carotene, α-carotene,
lycopene, β-cryptoxanthin) were inversely associated with
cardiovascular disease, total cancer, and/or all-cause mortality.
Carotenoids are mainly found in green and yellow fruits and
vegetables as well as dietary supplements. Intakes of fruits and
vegetables, raw vegetables, green or green and yellow vegetables,
and carrots are correlated with blood concentrations of total
carotenoids, α-carotene, and β-carotene (14, 91, 130, 131), and
studies have reported a reduced risk of coronary heart disease,
stroke, cardiovascular disease, total cancer, and/or all-cause
mortality with a high intake of these food sources of carotenoids
(11). Blood concentrations of β-cryptoxanthin correlate well with
total fruit and citrus fruit intake (91, 130, 131), whereas blood
concentrations of lycopene correlate with tomato and tomato
juice intake (91, 131–133). Intake of tomatoes has been inversely
associated with coronary heart disease, although associations
with other outcomes are less clear (11).
Dietary vitamin E was not significantly associated with
any of the outcomes in the linear dose-response analysis;
however, inverse associations were observed in the nonlinear
dose-response analysis, which might suggest that the nonlinear
analysis fit the data better. Blood concentrations of α-tocopherol
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FIGURE 11 Dietary β-carotene and blood concentrations of β-carotene and total cancer: dose-response analyses. (A) Dietary β-carotene and total cancer:
linear dose-response analysis. The summary RR per 5000 µg/d was 0.96 (95% CI: 0.90, 1.02, I2 = 25%, Pheterogeneity = 0.26, n = 4). (B) β-Carotene in
blood and total cancer: linear dose-response analysis. The summary RR per 25 µg/dL was 0.77 (95% CI: 0.68, 0.86, I2 = 0%, Pheterogeneity = 0.64, n = 7).
(C) Dietary β-carotene and total cancer: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary β-carotene and total cancer
(Pnonlinearity = 0.003). (D) β-Carotene in blood and total cancer: nonlinear dose-response analysis. There was evidence of nonlinearity for β-carotene in blood
and total cancer (Pnonlinearity = 0.60). Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response
analyses were conducted with the use of restricted cubic splines.
were inversely associated with risk of stroke, total cancer, and
all-cause mortality. Vitamin E is found mainly in vegetable
oils, nuts, seeds, and some fruits and vegetables, as well as
dietary supplements, and blood concentrations of α-tocopherol
are correlated with intake of fresh fruits and juices and
vegetables (134) and vitamin E from diet and supplements
(134, 135). Vitamin E intake may be less specific to the
intake of fruits and vegetables than vitamin C and carotenoids,
possibly accounting for the lack of association between dietary
vitamin E and cardiovascular disease, cancer, and mortality,
although nut intake has been inversely associated with these
outcomes (10).
The inverse associations between blood concentrations of
vitamin C, vitamin E, total carotenoids, and β-carotene with
disease and mortality endpoints were slightly stronger than for
dietary intake. However, the dose-response relation appeared to
be more often linear or nearly linear for the blood concentrations
of vitamin C, carotenoids, β-carotene, and β-cryptoxanthin and
mortality, than for both dietary antioxidant intake in the current
analysis and fruit and vegetable intake in our recent meta-
analysis (11), where most of the reduction in risk was observed
at the lower range of intakes. This could reflect a biological
saturation effect, an artifact due to measurement errors with
attenuation of the association at higher dietary intakes, or
other methodological issues. Vitamin C intake is most strongly
associated with plasma vitamin C concentrations at lower intakes,
and plasma vitamin C is less responsive at intakes >100–200
mg/d (136), which might explain the nonlinearity in the dietary
analyses.
Our results have some limitations. Confounding in both dietary
and biomarker studies by physical activity, less obesity, less
smoking, and lower intakes of red and processed meat is possible.
However, 1 study that used identical covariates for the analysis of
dietary intake and plasma concentrations of vitamin C in relation
to coronary heart disease risk suggested a stronger association
between plasma vitamin C and vitamin C intake estimated
from food-records compared with vitamin C intake estimated
from food frequency questionnaires (137). Reverse causation
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FIGURE 12 Dietary intake and blood concentrations of β-carotene and mortality: dose-response analyses. (A) Dietary β-carotene and mortality: linear
dose-response analysis. The summary RR per 5000 µg/d was 0.92 (95% CI: 0.85, 0.98, I2 = 66%, Pheterogeneity = 0.01, n = 6). (B) β-Carotene in blood
and mortality: linear dose-response analysis. The summary RR per 25 µg/dL was 0.81 (95% CI: 0.72, 0.90, I2 = 47%, Pheterogeneity = 0.08, n = 7).
(C) Dietary β-carotene and mortality: nonlinear dose-response analysis. There was evidence of nonlinearity between dietary β-carotene and mortality
(Pnonlinearity ≤ 0.0001). (D) β-Carotene in blood and mortality: nonlinear dose-response analysis. There was evidence of nonlinearity for β-carotene in blood
and mortality (Pnonlinearity = 0.005). Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response
analyses were conducted with the use of restricted cubic splines.
is also a possibility in studies of biomarkers of antioxidants
as antioxidants may be depleted due to oxidative stress or
inflammation during the disease process (138). However, this
explanation seems less likely as we found that the associations
persisted in subgroup analyses of studies that excluded prevalent
disease at baseline. In addition, there may have been some
inconsistencies between studies in the laboratory methods used
for the analyses of blood concentrations of antioxidants, which
may have contributed to heterogeneity between studies or could
potentially contribute to some of the nonlinear associations
observed. There was significant heterogeneity in several of
the analyses. Many of the inverse associations persisted in
subgroup analyses stratified by sex, location, number of cases,
and adjustment for confounding factors, but only in some of the
analyses was the heterogeneity explained. Studies of lycopene, α-
carotene, β-cryptoxanthin, and dietary carotenoids were small,
which limited the statistical power to detect an association
and the possibility to conduct subgroup analyses. Evidence of
small-study bias or publication bias in some of the analyses
suggested that the strength of the associations may have been
slightly overestimated in a few analyses, but this is unlikely
to substantially alter the overall findings of the study. One
last limitation is that there was no protocol for the current
review.
Dietary and biomarker studies have different strengths and
limitations. Dietary assessments of antioxidant vitamins and
carotenoids are prone to recall mismeasurement and do not
reflect bioavailability, but could be more time-integrated than a
single biomarker measure. Biomarkers reflect absorption being
influenced by the degree of processing or cooking of foods,
the lipid content of the diet, the degree of fermentation in the
colon, menstrual cycle and hormonal factors, and genetic factors
(32, 139). Further, metabolism of antioxidants and vitamins, as
well as smoking and high alcohol consumption, may reduce
blood concentrations of antioxidants (98, 140), which could
induce a bias not inherent in dietary studies, although fruit and
vegetable intakes explain more variability in plasma carotenoid
concentrations than do smoking and alcohol (141).
Strengths of our analysis include the prospective design and
high quality of the included studies, minimizing recall and
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FIGURE 13 Blood concentrations of α-carotene, β-cryptoxanthin, and lycopene and mortality: dose-response analyses. (A) Blood concentrations of α-
carotene and mortality: linear dose-response analysis. The summary RR per 10 µg/dL was 0.71 (95% CI: 0.64, 0.79, I2 = 0%, Pheterogeneity = 0.86, n = 5). (B)
Blood concentrations of β-cryptoxanthin and mortality: linear dose-response analysis. The summary RR per 15 µg/dL was 0.84 (95% CI: 0.76, 0.94, I2 = 0%,
Pheterogeneity = 0.99, n = 3). (C) Blood concentrations of lycopene and mortality: linear dose-response analysis. The summary RR per 25 µg/dL was 0.87
(95% CI: 0.74, 1.02, I2 = 26%, Pheterogeneity = 0.25, n= 5). (D) Blood concentrations of α-carotene and mortality, nonlinear dose-response analysis. There was
evidence of nonlinearity betweenα-carotene in blood andmortality (Pnonlinearity ≤ 0.0001). (E) Blood concentrations ofβ-cryptoxanthin andmortality: nonlinear
dose-response analysis. There was no evidence of nonlinearity for β-cryptoxanthin in blood and mortality (Pnonlinearity = 0.98). (F) Blood concentrations of
lycopene and mortality: nonlinear dose-response analysis. There was evidence of nonlinearity for lycopene in blood and mortality (Pnonlinearity = 0.001).
Summary RRs and 95% CIs were calculated with the use of random-effects models, and the nonlinear dose-response analyses were conducted using restricted
cubic splines.
selection bias; the large number of endpoints, which provide great
statistical power to detect associations; robustness of results from
numerous subgroup and sensitivity analyses; and the detailed
dose-response analyses, which clarified the strength and shape
of the dose-response relation. Finally, we analyzed both dietary
intake and biomarkers of vitamin C, vitamin E, and carotenoids,
and with the exception of vitamin E (for which the inverse associ-
ations were limited to the nonlinear dose-response analysis), we
found that both dietary intake and blood concentrations were in-
versely associated with risk of cardiovascular disease, cancer, and
mortality.
It is likely that the inverse associations between dietary intake
and blood concentrations of antioxidants we observed are not
due to the effect of single antioxidants but due to multiple
antioxidants and food components found in fruit and vegetables.
Randomized clinical trials have consistently shown no clear
benefit of antioxidant supplements on chronic disease risk and
even potential harms of supplementation of vitamin E and β-
carotene on mortality and lung cancer risk, respectively (142–
144). The randomized trials have used supplements with single
or a few antioxidants, whereas the observational studies have
assessed these nutrients based on blood concentrations or the
dietary intake of foods rich in these nutrients. The dietary
sources of these antioxidants (fruits, vegetables, berries, etc.)
also contain a myriad of other correlated bioactive compounds
that may have synergistic bioactivities. The results from the
observational studies could reflect a limited number of bioactive
compounds that have not been evaluated in randomized trials or
complex, interactive effects of multiple correlated beneficial food
components in plant foods. The current meta-analysis therefore
addresses a different question than the randomized trials and
is therefore not directly comparable with these. In line with
synergistic effects of multiple components is a recent randomized
intervention study that supplemented diets with kiwi fruit and
by using gene expression profiles as proxy outcome, the study
indicated that the phytochemicals work in concert rather than
individually (145).
Although a combined total antioxidant score may be more
strongly correlated with fruit and vegetable intake than individual
antioxidants, to date only a few studies have used a total
dietary antioxidant score (51, 54, 127, 146, 147) and the results
are not substantially different than for individual antioxidants
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FIGURE 14 (A) Dietary intake of vitamin E and mortality: linear dose-response analysis. The summary RR per 5 µg/d was 0.99 (95% CI: 0.96, 1.01,
I2 = 42%, Pheterogeneity = 0.10, n = 8). (B) Blood concentrations of α-tocopherol and mortality: linear dose-response analysis. The summary RR per 500
µg/dL was 0.94 (95% CI: 0.90, 0.98, I2 = 43%, Pheterogeneity = 0.09, n = 8). (C) Dietary intake of vitamin E and mortality: nonlinear dose-response analysis.
There was evidence of nonlinearity between dietary vitamin E and mortality (Pnonlinearity < 0.0001). (D) Blood concentrations of α-tocopherol and mortality:
nonlinear dose-response analysis. There was indication of nonlinearity for α-tocopherol in blood and mortality (Pnonlinearity = 0.05). Summary RRs and 95%
CIs were calculated with the use of random-effects models, and the nonlinear dose-response analyses were conducted with the use of restricted cubic splines.
SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study.
(51, 54, 127, 146, 147). We did not identify any studies
that used a total antioxidant biomarker. In addition, other,
more specific biomarkers (e.g., metabolomics) may enable
distinguishing between types of fruits and vegetables in the
future (148, 149). Intervention studies have shown increases in
serum concentrations of vitamin C and carotenoids with higher
intakes of fruits and vegetables (150). However, the size of
the increase in blood concentrations was relatively moderate
compared with the amount of fruits and vegetables eaten and
the range of the blood concentrations of antioxidants observed
in the current meta-analysis. Thus, we cannot exclude the
possibility that other factors may contribute, at least partly, to
the beneficial effect observed of high serum concentrations of
antioxidants. The different vitamin C and carotenoid contents
of individual fruits and vegetables make it difficult to quantify
the amount of fruit and vegetables required to increase the
blood concentration of vitamin C or carotenoids by a certain
amount.
Together with largely null findings of randomized clinical
trials on dietary antioxidant supplements and chronic disease
prevention, the current findings have importance for public health
because they support dietary recommendations to increase intake
of fruit and vegetables (11), but not supplements, to reduce the
risk of chronic diseases and premature mortality. Any further
studies should investigate associations between less investigated
antioxidants or overall antioxidant scores in both diet and blood
and these outcomes as well as less common disease outcomes
that have been less investigated to date and might benefit from
incorporating repeated measures of diet and blood samples.
In conclusion, higher dietary intake and/or blood concentra-
tions of vitamin C, carotenoids, and α-tocopherol (as markers of
fruit, vegetable, and nut intake) were associated with reduced risk
of cardiovascular disease, total cancer, and all-cause mortality.
It is likely that the associations observed are not due to the
individual antioxidants themselves, but rather the combination of
multiple beneficial components in fruits and vegetables. These
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results support the notion that a high intake of fruits and
vegetables, especially those high in vitamin C and carotenoids,
reduces the risk of cardiovascular disease, cancer, and premature
mortality.
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